High Vista Strategies LLC Tricida, Inc. Transaction History

High Vista Strategies LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $12,101 - $19,339	1,422 Added 2.07%	69,970 $733,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $11.85 $282,560 - $458,049	-38,654 Reduced 36.06%	68,548 $664,000
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $787,934 - $1.14 Million	107,202 New	107,202 $881,000
Q3 2020 Nov 16, 2020	SELL	$8.56 - $26.93 $138,971 - $437,208	-16,235 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $344,344 - $512,214	16,235 New	16,235 $446,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.